Cerebrolysin
Star4
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Summary
Cerebrolysin is a proteolytic protein indicated in the treatment of cerebrovascular disorders.
- Generic Name
- Cerebrolysin
- DrugBank Accession Number
- DB16599
- Background
Not Available
- Type
- Biotech
- Groups
- Experimental
- Synonyms
- Cerebrolyzin
- External IDs
- FPE 1070
- FPF 1070
- FPF-1070
- FPF1070
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Adjunct therapy in treatment of Alzheimer's disease (ad) •••••••••••• •••••••• Used as adjunct for symptomatic treatment of Cerebrovascular accident •••••••••••• •••••••• Adjunct therapy in treatment of Cerebrovascular diseases •••••••••••• •••••••• Adjunct therapy in treatment of Craniocerebral trauma •••••••••••• •••••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 37KZM6S21G
- CAS number
- 12656-61-0
References
- General References
- BASG: Ambotonin (Cerebrolysin) Intramuscular, Intravenous Injection [Link]
- External Links
- Wikipedia
- Cerebrolysin
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample dataNot Available Active Not Recruiting Not Available Acute Ischemic Stroke 1 somestatus stop reason just information to hide Not Available Completed Not Available Traumatic Brain Injury (TBI) 1 somestatus stop reason just information to hide Not Available Completed Basic Science Hair Problems 1 somestatus stop reason just information to hide Not Available Enrolling by Invitation Prevention Brain Injury / Cardiac Diseases / Critically Ill Patients / Neurocognitive Disorders / Surgical Complications 1 somestatus stop reason just information to hide Not Available Recruiting Treatment Acute Ischemic Stroke 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, solution, concentrate Parenteral 215.2 mg/ml Solution Intramuscular; Intravenous 215 mg/mL Solution Intravenous 215.200 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at February 16, 2021 15:12 / Updated at July 18, 2023 22:58